Pfizer Posts Revenue Decline in Q1 2025, Highlights Strategic Focus

Pfizer’s Q1 2025 financial report reveals a revenue decrease of 8% compared to the previous year, attributed primarily to reduced Paxlovid sales. Despite this decline, the company reported strong earnings performance driven by operational efficiency and cost management. Pfizer reaffirmed its full-year 2025 guidance for revenue between $61 and $64 billion, highlighting a strategic focus on research and development as well as cost optimization.